Literature DB >> 22219169

DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.

Noël J-M Raynal1, Jiali Si, Rodolphe F Taby, Vazganush Gharibyan, Saira Ahmed, Jaroslav Jelinek, Marcos R H Estécio, Jean-Pierre J Issa.   

Abstract

DNA methylation is commonly thought of as a "molecular lock" that leads to permanent gene silencing. To investigate this notion, we tested 24 different histone deacetylase inhibitors (HDACi) on colon cancer cells that harbor a GFP locus stably integrated and silenced by a hypermethylated cytomegalovirus (CMV) promoter. We found that HDACi efficiently reactivated expression of GFP and many other endogenous genes silenced by DNA hypermethylation. After treatment, all promoters were marked with active chromatin, yet DNA hypermethylation did not change. Thus, DNA methylation could not prevent gene reactivation by drug-induced resetting of the chromatin state. In evaluating the relative contribution of DNA methylation and histone modifications to stable gene silencing, we followed expression levels of GFP and other genes silenced by DNA hypermethylation over time after treatment with HDACi or DNA-demethylating drugs. Reactivation of methylated loci by HDACi was detectable for only 2 weeks, whereas DNA-demethylating drugs induced permanent epigenetic reprogramming. Therefore, DNA methylation cannot be considered as a lock for gene expression but rather as a memory signal for long-term maintenance of gene silencing. These findings define chromatin as an important druggable target for cancer epigenetic therapy and suggest that removal of DNA methylation signals is required to achieve long-term gene reactivation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22219169      PMCID: PMC3294136          DOI: 10.1158/0008-5472.CAN-11-3248

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy.

Authors:  Jacob D Kagey; Priya Kapoor-Vazirani; Michael T McCabe; Doris R Powell; Paula M Vertino
Journal:  Mol Cancer Res       Date:  2010-06-29       Impact factor: 5.852

Review 2.  Linking DNA methylation and histone modification: patterns and paradigms.

Authors:  Howard Cedar; Yehudit Bergman
Journal:  Nat Rev Genet       Date:  2009-05       Impact factor: 53.242

Review 3.  Cancer epigenetics.

Authors:  Rodolphe Taby; Jean-Pierre J Issa
Journal:  CA Cancer J Clin       Date:  2010-10-19       Impact factor: 508.702

4.  Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.

Authors:  Jiali Si; Yanis A Boumber; Jingmin Shu; Taichun Qin; Saira Ahmed; Rong He; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2010-08-16       Impact factor: 12.701

5.  Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.

Authors:  J S You; J K Kang; E K Lee; J C Lee; S H Lee; Y J Jeon; D H Koh; S H Ahn; D-W Seo; H Y Lee; E-J Cho; J-W Han
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

6.  Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.

Authors:  Chun-Feng Meng; Xin-Jiang Zhu; Guo Peng; Dong-Qiu Dai
Journal:  Oncol Rep       Date:  2009-11       Impact factor: 3.906

Review 7.  Epigenetics in cancer.

Authors:  Shikhar Sharma; Theresa K Kelly; Peter A Jones
Journal:  Carcinogenesis       Date:  2009-09-13       Impact factor: 4.944

8.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.

Authors:  Yutaka Kondo; Lanlan Shen; Alfred S Cheng; Saira Ahmed; Yanis Boumber; Chantale Charo; Tadanori Yamochi; Takeshi Urano; Koichi Furukawa; Bernard Kwabi-Addo; David L Gold; Yoshitaka Sekido; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal:  Nat Genet       Date:  2008-05-18       Impact factor: 38.330

9.  High-throughput methylation profiling by MCA coupled to CpG island microarray.

Authors:  Marcos R H Estécio; Pearlly S Yan; Ashraf E K Ibrahim; Carmen S Tellez; Lanlan Shen; Tim H-M Huang; Jean-Pierre J Issa
Journal:  Genome Res       Date:  2007-09-04       Impact factor: 9.043

10.  DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

Authors:  Tina Branscombe Miranda; Connie C Cortez; Christine B Yoo; Gangning Liang; Masanobu Abe; Theresa K Kelly; Victor E Marquez; Peter A Jones
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

View more
  62 in total

1.  Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.

Authors:  Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski
Journal:  Int J Cancer       Date:  2013-09-30       Impact factor: 7.396

2.  H3K9 trimethylation precedes DNA methylation during sheep oogenesis: HDAC1, SUV39H1, G9a, HP1, and Dnmts are involved in these epigenetic events.

Authors:  Valentina Russo; Nicola Bernabò; Oriana Di Giacinto; Alessandra Martelli; Annunziata Mauro; Paolo Berardinelli; Valentina Curini; Delia Nardinocchi; Mauro Mattioli; Barbara Barboni
Journal:  J Histochem Cytochem       Date:  2012-09-26       Impact factor: 2.479

Review 3.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

4.  Transcriptional Selectivity of Epigenetic Therapy in Cancer.

Authors:  Takahiro Sato; Matteo Cesaroni; Woonbok Chung; Shoghag Panjarian; Anthony Tran; Jozef Madzo; Yasuyuki Okamoto; Hanghang Zhang; Xiaowei Chen; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2016-11-22       Impact factor: 12.701

5.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

6.  Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.

Authors:  Kenji Makita; Riko Kitazawa; Shuho Semba; Koto Fujiishi; Miku Nakagawa; Ryuma Haraguchi; Sohei Kitazawa
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Authors:  Hanghang Zhang; Somnath Pandey; Meghan Travers; Hongxing Sun; George Morton; Jozef Madzo; Woonbok Chung; Jittasak Khowsathit; Oscar Perez-Leal; Carlos A Barrero; Carmen Merali; Yasuyuki Okamoto; Takahiro Sato; Joshua Pan; Judit Garriga; Natarajan V Bhanu; Johayra Simithy; Bela Patel; Jian Huang; Noël J-M Raynal; Benjamin A Garcia; Marlene A Jacobson; Cigall Kadoch; Salim Merali; Yi Zhang; Wayne Childers; Magid Abou-Gharbia; John Karanicolas; Stephen B Baylin; Cynthia A Zahnow; Jaroslav Jelinek; Xavier Graña; Jean-Pierre J Issa
Journal:  Cell       Date:  2018-10-25       Impact factor: 41.582

8.  The epigenome of AML stem and progenitor cells.

Authors:  Jumpei Yamazaki; Marcos R Estecio; Yue Lu; Hai Long; Gabriel G Malouf; David Graber; Yujia Huo; Louis Ramagli; Shoudan Liang; Steven M Kornblau; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Epigenetics       Date:  2012-12-18       Impact factor: 4.528

Review 9.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

10.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.